RxDoctor Payments Data

Jonathan Mikhail, MD

Family Medicine · Tuscaloosa, ALNPI 1275151284

Payments from drug & device makers

$929in general payments, 2019–2025

Across 52 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$245
  • AstraZeneca$135
  • Novo Nordisk$111
  • AbbVie$107
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$70
  • Lilly USA, LLC$42
  • plus $220 from 8 others

What the payments were for

  • Food & beverage$90998%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$929 in reported general payments places this provider in the 55th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$41,326
Medicare patients
124
Services billed
538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide37$50,471
JardianceEmpagliflozin32$41,995
EliquisApixaban36$34,745
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$27,229
FarxigaDapagliflozin Propanediol23$26,315
XareltoRivaroxaban21$20,196
OzempicSemaglutide18$17,198
BrilintaTicagrelor17$9,345
VascepaIcosapent Ethyl14$9,217
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,902
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$4,188
ShingrixVaricella-Zoster Ge/As01b/Pf15$3,067
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$2,464
Rosuvastatin Calcium89$2,192
Albuterol Sulfate HfaAlbuterol Sulfate91$2,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$42$50,47137 claims
AstraZenecaFarxiga, Brilinta, Breztri Aerosphere$135$42,56251 claims
PfizerEliquis$39$34,74536 claims
GSKTrelegy Ellipta, Shingrix$245$30,29656 claims
Novo NordiskOzempic$111$17,19818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →